NIRAVAM Drug Patent Profile
✉ Email this page to a colleague
When do Niravam patents expire, and what generic alternatives are available?
Niravam is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the alprazolam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Niravam
A generic version of NIRAVAM was approved as alprazolam by NOVITIUM PHARMA on October 19th, 1993.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NIRAVAM?
- What are the global sales for NIRAVAM?
- What is Average Wholesale Price for NIRAVAM?
Summary for NIRAVAM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 53 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,477 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NIRAVAM |
| What excipients (inactive ingredients) are in NIRAVAM? | NIRAVAM excipients list |
| DailyMed Link: | NIRAVAM at DailyMed |
Recent Clinical Trials for NIRAVAM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Actavis Inc. | Phase 1 |
| UCB Pharma | Phase 4 |
Paragraph IV (Patent) Challenges for NIRAVAM
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| NIRAVAM | Orally Disintegrating Tablets | alprazolam | 0.25 mg, 0.5 mg, 1 mg and 2 mg | 021726 | 1 | 2005-12-27 |
US Patents and Regulatory Information for NIRAVAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-001 | Jan 19, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-004 | Jan 19, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-002 | Jan 19, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-003 | Jan 19, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NIRAVAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-001 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-002 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-003 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-004 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-004 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-003 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-002 | Jan 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NIRAVAM
See the table below for patents covering NIRAVAM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2147669 | Formule de dosage robuste à dissolution rapide (Rapidly dissolving robust dosage form) | ⤷ Sign Up |
| Denmark | 2266538 | ⤷ Sign Up | |
| Australia | 726336 | ⤷ Sign Up | |
| Japan | 2012162558 | RAPIDLY DISSOLVING ROBUST DOSAGE FORM | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 9846215 | ⤷ Sign Up | |
| Canada | 2284663 | DISSOLUTION RAPIDE DE FORME POSOLOGIQUE DE BONNE TENUE (RAPIDLY DISSOLVING ROBUST DOSAGE FORM) | ⤷ Sign Up |
| Portugal | 2147669 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
